Investigating the efficacy of baricitinib in new onset type 1 diabetes mellitus (BANDIT)—study protocol for a phase 2, randomized, placebo controlled trial

BACKGROUND: Type 1 diabetes (T1D) places an extraordinary burden on individuals and their families, as well as on the healthcare system. Despite recent advances in glucose sensors and insulin pump technology, only a minority of patients meet their glucose targets and face the risk of both acute and...

Descripción completa

Detalles Bibliográficos
Autores principales: Waibel, M., Thomas, H. E., Wentworth, J. M., Couper, J. J., MacIsaac, R. J., Cameron, F. J., So, M., Krishnamurthy, B., Doyle, M. C., Kay, T. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125350/
https://www.ncbi.nlm.nih.gov/pubmed/35606820
http://dx.doi.org/10.1186/s13063-022-06356-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125350/
https://www.ncbi.nlm.nih.gov/pubmed/35606820
http://dx.doi.org/10.1186/s13063-022-06356-z

Ejemplares similares